ALAN MERTZ

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R. 34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.; P.L. 114-223, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, FY2017, and Zika Response Preparedness Act; P.L. 114-254 Further Continuing and Security Assistance Appropriations Act, 2017

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and FY2017 Agriculture Appropriations.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R. 34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R. 34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R.34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R. 34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.; P.L. 114-223, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, FY2017, and Zika Response Preparedness Act; P.L. 114-254 Further Continuing and Security Assistance Appropriations Act, 2017

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R. 34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R. 34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.; P.L. 114-223, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, FY2017, and Zika Response Preparedness Act; P.L. 114-254 Further Continuing and Security Assistance Appropriations Act, 2017

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R. 34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.; P.L. 114-223, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, FY2017, and Zika Response Preparedness Act; P.L. 114-254 Further Continuing and Security Assistance Appropriations Act, 2017

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and FY2017 Agriculture Appropriations.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R. 34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R.34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and FY2017 Agriculture Appropriations.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R. 34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.; P.L. 114-223, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, FY2017, and Zika Response Preparedness Act; P.L. 114-254 Further Continuing and Security Assistance Appropriations Act, 2017

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; 21st Century Cures Initiative; the regulation and oversight of clinical laboratories; H.Con.Res.27 Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, Setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Medicare reimbursement under the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including cost-sharing for clinical laboratory services under Part B; narrowing the Medicare in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27 Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; and S. Con. Res. 11, Setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; the regulation and oversight of clinical laboratories; H.Con.Res.27 Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, Setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; 21st Century Cures Initiative; the regulation and oversight of clinical laboratories; H.Con.Res.27 Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, Setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; the regulation and oversight of clinical laboratories; H.Con.Res.27 Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, Setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.